πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

2,762 results for β€œCTI” Clear

  1. OXALIPLATIN, PANITUMUMAB, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, BEVACIZUMAB, NIVOLUMAB, TRASTUZUMAB

    Ningbo Cancer Hospital

    Patients with pMMR/MSS metastatic adenocarcinoma of the colon or rectum or gastroesophageal cancer (lower esophagus, gastroesophageal junction and gastric) and with known dihydropyrimidine dehydrogenase (DPD) deficiency defined as plasma uracil concentration β‰₯16 ng/ml, who undergo first-line treatment

    phase 2 small molecule active

    1 trial
  2. Obexelimab, Placebo sterile solution for SC injection, PREDNISOLONE

    Zenas BioPharma

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial
  3. Obinutuzumab Injection [Gazyva]

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Immune Thrombocytopenia

    phase 2 small molecule active

    2 trials
  4. Ocrevus 300 mg concentrate for solution for infusion, CYTARABINE, CARMUSTINE, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, Tysabri 300 mg concentrate for solution for infusion, CARMUSTINE, ETOPOSIDE, CARMUSTINE, UBLITUXIMAB, MELPHALAN FLUFENAMIDE, FILGRASTIM, FILGRASTIM, CYTARABINE, CYTARABINE, CYCLOPHOSPHAMIDE, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, Kesimpta 20 mg solution for injection in pre-filled pen, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, CYTARABINE, LEMTRADA 12 mg concentrate for solution f

    Fondazione Telethon ETS

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule active

    1 trial
  5. Ocrevus, Ocrevus 920 mg solution for injection, Ocrevus, Ocrelizumab

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 2 small molecule active

    1 trial
  6. Octacalcium phosphate

    The First People's Hospital of Lianyungang

    Tooth Extraction

    phase 2 other completed

    1 trial
  7. Olorofim

    Biotech Pharmaceutical Co.,

    Invasive Fungal Infections

    phase 2 small molecule completed

    1 trial
  8. Ondansetron Aurobindo 8 mg Filmtabletten, Dexamethasone 4 mg tablets, ZYPREXA 2.5 mg coated tablets, SELINEXOR, Bortezomib Accord 3.5 mg powder for solution for injection

    Karyopharm Therapeutics Inc

    Penta-refractory multiple myeloma and triple-class refractory multiple myeloma

    phase 2 small molecule active

    1 trial
  9. Opaganib

    RedHill Biopharma

    Coronavirus Infections

    phase 2 small molecule completed

    1 trial
  10. Open-Label

    Jazz Pharmaceuticals Ireland Limited

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial
  11. Ozempic 0.25 mg solution for injection in pre-filled pen, Ozempic 0.5 mg solution for injection in pre-filled pen, Ozempic 1 mg solution for injection in pre-filled pen

    The George Institute

    Craving for and use of chemsex-related drugs

    phase 2 small molecule active

    1 trial
  12. PARACETAMOL, Placebo to QUC398 150 mg/1 mL Solution for injection, QUC398, Paracetamol/Codeine phosphate hemihydrate Accord 500 mg/30 mg tablets

    Novartis Pharmaceuticals

    Knee osteoarthritis

    phase 2 small molecule active

    1 trial
  13. PCI

    Rhythm Pharmaceuticals Netherlands B.V.

    Myocardial Infarction

    phase 2 other completed

    1 trial
  14. PD-1/CTLA-4 Dual Functional Antibody

    The First People's Hospital of Lianyungang

    Bile Duct Carcinoma

    phase 2 small molecule active

    1 trial
  15. PDC-1421 Capsule

    ABVC BIOPHARMA, INC.

    Attention-Deficit Hyperactivity Disorder (ADHD)

    phase 2 small molecule completed

    1 trial
  16. PEG-IFNΞ±

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial
  17. PEMBROLIZUMAB , EIK1001 solution for injection 1.0 mg/mL free base equivalent, Inactive control which is identical in appearance and composition as EIK1001 drug product except for the lack of EIK1001 drug substance

    Eikon Therapeutics

    Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial
  18. PENNVAX-GP

    INOVIO PHARMACEUTICALS, INC.

    HIV-1-infection

    phase 2 mab completed

    1 trial
  19. PF-00547659 SC injection

    Takeda

    Crohn's Disease

    phase 2 small molecule completed

    1 trial
  20. PF-04236921 SC injection

    Pfizer

    Crohn's Disease

    phase 2 small molecule completed

    1 trial
  21. PH-797804

    Pfizer

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial
  22. PHITAH

    Lxo Ireland Designated Activity Company

    Basal Cell Carcinoma

    phase 2 mab active

    1 trial
  23. PLACEBO, BELTAVAC polymerized grass mix, BELTAVAC polymerized grass mix, -

    Lacuna Pharma Pty Ltd

    allergic rhinoconjunctivitis caused due to exposure to pollen grasses

    phase 2 small molecule active

    1 trial
  24. PLACEBO, BELTAVAC polymerized grass mix, BELTAVAC polymerized grass mix, BELTAVAC polymerized grass mix, -

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis caused due to exposure to pollen grasses

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources